MedTrace Logo

Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients

NCT03090893 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2018-09-10

No results posted yet for this study

Summary

The objective of this study will be to prospectively evaluate the response of a continuous infusion of recombinant human antithrombin concentrate (rhAT) (ATRYN®) to achieve and maintain the AT activity within a specified range in adult patients that require extracorporeal membrane oxygenation (ECMO) following cardiopulmonary bypass (CPB) and cardiac surgery.

Conditions

  • Antithrombin Deficiency Type 2

Interventions

DRUG

ATryn continuous infusion

replenish serum thrombin levels

Sponsors & Collaborators

  • rEVO Biologics

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • William C. Oliver, Jr., MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-06-30
Completion
2019-06-30
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03090893 on ClinicalTrials.gov